{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:12:00Z","timestamp":1769155920961,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The course of monkeypox can be severe. Our aim was to retrospectively compare the risk of hospital admission, the need for ventilation, sepsis, pneumonitis and death between the recent outbreak and historical outbreaks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and Methods<\/jats:title>\n                <jats:p>Cases of monkeypox were retrieved from the TriNetX database and assigned to either cohort I (recent outbreak between May 1st and September 16th, 2022) and cohort II (historical outbreaks before May 1st, 2022). After matching for age distribution, statistical analysis was performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 640 patients with monkeypox 81 subjects per cohort remained after matching (mean age\u00b1standard deviation\u2009=\u200936.1\u00b118.3 years). Within 56 days after diagnosis 10 patients per cohort were hospitalized (12.4%) and\/or developed sepsis (12.4%). The risk of ventilation and pneumonitis were significantly lower among cohort I compared with cohort II (0 vs. 10 cases; risk difference\u2009=\u200912.4%; p\u2009=\u20090.001; Log-Rank test). No cases of death were recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Even though monkeypox provides a risk of severe courses, the infection is self-limiting in most cases. Unlike past outbreaks, the risk of ventilation and pneumonitis may be relatively low among recent outbreaks.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08599-w","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T08:02:07Z","timestamp":1695024127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of the risk of hospital admission, need for ventilation, sepsis, pneumonitis and death among the recent monkeypox outbreak and historical outbreaks"],"prefix":"10.1186","volume":"23","author":[{"given":"Florian","family":"Gaertner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia","family":"Preissner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"William Arthur","family":"Petri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olubunmi","family":"Atolani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Heiland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Nahles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Preissner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Hertel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"8599_CR1","unstructured":"Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis. 2022."},{"issue":"12","key":"8599_CR2","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1086\/498115","volume":"41","author":"GD Huhn","year":"2005","unstructured":"Huhn GD, Bauer AM, Yorita K, Graham MB, Sejvar J, Likos A, et al. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin Infect Dis. 2005;41(12):1742\u201351.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"8599_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/09564624221141152","volume":"34","author":"L Labate","year":"2023","unstructured":"Labate L, Brucci G, Ciccarese G, Bruzzone B, Ricucci V, Stefanelli F, et al. Nasal monkeypox virus infection successfully treated with cidofovir in a patient newly diagnosed with HIV. Int J STD AIDS. 2023;34(3):208\u201310.","journal-title":"Int J STD AIDS"},{"issue":"2","key":"8599_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s15010-022-01949-x","volume":"51","author":"C Fabrizio","year":"2023","unstructured":"Fabrizio C, Bruno G, Cristiano L, Buccoliero GB. Cidofovir for treating complicated monkeypox in a man with acquired immune deficiency syndrome. Infection. 2023;51(2):519\u201322.","journal-title":"Infection"},{"issue":"9","key":"8599_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nm1273","volume":"11","author":"E Hammarlund","year":"2005","unstructured":"Hammarlund E, Lewis MW, Carter SV, Amanna I, Hansen SG, Strelow LI, et al. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med. 2005;11(9):1005\u201311.","journal-title":"Nat Med"},{"key":"8599_CR6","doi-asserted-by":"crossref","unstructured":"Velavan TP, Meyer CG. Monkeypox 2022 outbreak: an update. Trop Med Int Health. 2022.","DOI":"10.1111\/tmi.13785"},{"key":"8599_CR7","doi-asserted-by":"crossref","unstructured":"Kumar S, Subramaniam G, Karuppanan K. Human monkeypox outbreak in 2022. J Med Virol. 2022.","DOI":"10.1002\/jmv.27894"},{"key":"8599_CR8","doi-asserted-by":"crossref","unstructured":"Centor RM, Adalja A. Annals on Call - Monkeypox: should we worry about another pandemic? Ann Intern Med. 2022:OC1.","DOI":"10.7326\/A21-0014"},{"key":"8599_CR9","doi-asserted-by":"crossref","unstructured":"Kozlov M. Monkeypox outbreaks: 4 key questions researchers have. Nature. 2022.","DOI":"10.1038\/d41586-022-01493-6"},{"issue":"10","key":"8599_CR10","doi-asserted-by":"publisher","first-page":"e0007791","DOI":"10.1371\/journal.pntd.0007791","volume":"13","author":"EM Beer","year":"2019","unstructured":"Beer EM, Rao VB. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Negl Trop Dis. 2019;13(10):e0007791.","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"8599_CR11","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1093\/cid\/ciaa143","volume":"71","author":"D Ogoina","year":"2020","unstructured":"Ogoina D, Iroezindu M, James HI, Oladokun R, Yinka-Ogunleye A, Wakama P, et al. Clinical course and outcome of human monkeypox in Nigeria. Clin Infect Dis. 2020;71(8):e210\u2013e4.","journal-title":"Clin Infect Dis"},{"key":"8599_CR12","doi-asserted-by":"crossref","unstructured":"Martin-Delgado MC, Martin Sanchez FJ, Martinez-Selles M, Molero Garcia JM, Moreno Guillen S, Rodriguez-Artalejo FJ et al. Monkeypox in humans: a new outbreak. Rev Esp Quimioter. 2022.","DOI":"10.37201\/req\/059.2022"},{"key":"8599_CR13","doi-asserted-by":"crossref","unstructured":"Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB et al. Monkeypox Virus infection in humans across 16 Countries - April-June 2022. N Engl J Med. 2022.","DOI":"10.1056\/NEJMoa2207323"},{"issue":"1","key":"8599_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41392-021-00689-y","volume":"6","author":"C Mura","year":"2021","unstructured":"Mura C, Preissner S, Nahles S, Heiland M, Bourne PE, Preissner R. Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients. Signal Transduct Target Ther. 2021;6(1):267.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"8599_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12916-020-01851-z","volume":"18","author":"U Seeland","year":"2020","unstructured":"Seeland U, Coluzzi F, Simmaco M, Mura C, Bourne PE, Heiland M, et al. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. BMC Med. 2020;18(1):369.","journal-title":"BMC Med"},{"key":"8599_CR16","doi-asserted-by":"crossref","unstructured":"Hertel M, Schmidt-Westhausen AM, Wendy S, Heiland M, Nahles S, Preissner R et al. Onset of oral lichenoid lesions and oral Lichen Planus following COVID-19 vaccination: a retrospective analysis of about 300,000 vaccinated patients. Vaccines (Basel). 2022;10(3).","DOI":"10.3390\/vaccines10030480"},{"issue":"2","key":"8599_CR17","doi-asserted-by":"publisher","first-page":"e0010141","DOI":"10.1371\/journal.pntd.0010141","volume":"16","author":"EM Bunge","year":"2022","unstructured":"Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis. 2022;16(2):e0010141.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"8599_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.virol.2005.05.030","volume":"340","author":"N Chen","year":"2005","unstructured":"Chen N, Li G, Liszewski MK, Atkinson JP, Jahrling PB, Feng Z, et al. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology. 2005;340(1):46\u201363.","journal-title":"Virology"},{"key":"8599_CR19","unstructured":"[Available from: https:\/\/www.who.int\/publications\/m\/item\/multi-country-outbreak-of-monkeypox--external-situation-report--4---24-august-2022."},{"issue":"4","key":"8599_CR20","doi-asserted-by":"publisher","first-page":"718","DOI":"10.4269\/ajtmh.15-0095","volume":"93","author":"AM McCollum","year":"2015","unstructured":"McCollum AM, Nakazawa Y, Ndongala GM, Pukuta E, Karhemere S, Lushima RS, et al. Human monkeypox in the Kivus, a Conflict Region of the Democratic Republic of the Congo. Am J Trop Med Hyg. 2015;93(4):718\u201321.","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"8599_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4269\/ajtmh.2005.73.428","volume":"73","author":"LA Learned","year":"2005","unstructured":"Learned LA, Reynolds MG, Wassa DW, Li Y, Olson VA, Karem K, et al. Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg. 2005;73(2):428\u201334.","journal-title":"Am J Trop Med Hyg"},{"key":"8599_CR22","unstructured":"https:\/\/trinetx.com\/trinetx-publication-guidelines\/."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08599-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08599-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08599-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T16:08:36Z","timestamp":1700496516000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08599-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8599"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08599-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"assertion":[{"value":"17 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work was reviewed by the Institutional Review Board (IRB) for Health Sciences Research of the University of Virginia (IRB tracking ID #23100), which determined that this project did not meet the criteria for Human Subject Research; the IRB deemed no further submission\/review necessary to proceed with this project.All methods were carried out in accordance with relevant guidelines and regulations.The need for informed consent was waived by the Institutional Review Board (IRB) for Health Sciences Research of the University of Virginia (IRB tracking ID #23100) because of the retrospective nature of the study.TriNetX is compliant with the Health Insurance Portability and Accountability Act (HIPAA), the US federal law which protects the privacy and security of healthcare data. TriNetX is certified to the ISO 27001:2013 standard and maintains an Information Security Management System (ISMS) to ensure protection of the healthcare data it has access to and to meet the requirements of the HIPAA Security Rule. Any data displayed on the TriNetX Platform in aggregate form, or any patient level data provided in a data set generated by the TriNetX Platform, is de-identified according to the de-identification standard defined in Section \u00a7\u00a0164.514(a) of the HIPAA Privacy Rule. The process by which the data are de-identified is attested to through a formal determination by a qualified expert, as defined in Section \u00a7\u00a0164.514(b) [] of the HIPAA Privacy Rule. This formal determination by a qualified expert, refreshed in December 2020, supersedes the need for TriNetX\u2019s previous waiver from the Western Institutional Review Board (IRB). The TriNetX network contains data provided by participating HCOs, each of which represents and warrants that it has all necessary rights, consents, approvals and authority to provide the data to TriNetX under a Business Associate Agreement (BAA), so long as their name remains anonymous as a data source and their data are utilised for research purposes. The data shared through the TriNetX Platform are minimised to ensure that they do not include sufficient information to facilitate the determination of which HCO contributed specific information about a patient [].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"610"}}